Real-World Evidence for Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Scoping Review.

ABSTRACT:

Purpose

Since faricimab (Vabysmo) was approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), a growing body of real-world data has been reported, forming an important source of evidence for faricimab in a heterogeneous population. Scoping reviews are an effective approach to comprehensively assess the state of evidence on areas yet to be well characterized, allowing for the inclusion of a wide range of study designs and methodologies. This scoping review aimed to assess the current breadth and nature of real-world evidence (RWE) for faricimab and describe its safety and effectiveness in routine clinical practice.

Design

Scoping review of published articles and grey literature.

Participants

Eligible records i

SUBMITTER: Chaudhary V 

PROVIDER: S-EPMC12002985 | biostudies-literature | 2025 Jul-Aug

REPOSITORIES: biostudies-literature